{"transactions":[{"id":1650521,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2024-02-12T18:23:53.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":190000,"price":12.95,"value":2460500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by Abingworth Bioventures VII LP (\"ABV VII\"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any."}],"balance_after":1066189,"source":{"system":"sec-edgar","filing":"0000950170-24-014017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000095017024014017/ownership.xml","form_type":"4"}},{"id":1771064,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Prefunded Warrants","published_at":"2023-10-02T19:54:09.000Z","date":"2023-09-28","kind":"exercise","planned":false,"acquired":true,"shares":762126,"price":1.75,"value":1333720.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2023, Abingworth Bioventures VII LP (\"ABV VII\") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the \"Prefunded Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":762126,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":762126},"source":{"system":"sec-edgar","filing":"0000899243-23-019658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323019658/doc4.xml","form_type":"4"}},{"id":1771063,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-10-02T19:54:09.000Z","date":"2023-09-28","kind":"exercise","planned":false,"acquired":false,"shares":1092056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2023, Abingworth Bioventures VII LP (\"ABV VII\") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the \"Prefunded Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":1092056},"source":{"system":"sec-edgar","filing":"0000899243-23-019658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323019658/doc4.xml","form_type":"4"}},{"id":1771062,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T19:54:09.000Z","date":"2023-09-28","kind":"exercise","planned":false,"acquired":true,"shares":329930,"price":1.75,"value":577377.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2023, Abingworth Bioventures VII LP (\"ABV VII\") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the \"Prefunded Warrants\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":1531436,"source":{"system":"sec-edgar","filing":"0000899243-23-019658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323019658/doc4.xml","form_type":"4"}},{"id":1898700,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Warrants","published_at":"2023-05-10T16:30:14.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":1778000,"price":0.4425,"value":786765.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche B Warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance and 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS. However, the Tranche B Warrants contain provisions preventing the Tranche B Warrants from being exercised if such exercise would result in ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche B Warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance and 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS. However, the Tranche B Warrants contain provisions preventing the Tranche B Warrants from being exercised if such exercise would result in ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":1778000,"derivative":{"exercise_price":2.5,"underlying":"Common Stock","underlying_shares":1778000},"source":{"system":"sec-edgar","filing":"0000899243-23-012501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323012501/doc4.xml","form_type":"4"}},{"id":1898699,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-05-10T16:30:14.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":1092056,"price":0.4425,"value":483234.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result Abingworth Bioventures VII LP (\"ABV VII\") obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result Abingworth Bioventures VII LP (\"ABV VII\") obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":1092056,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":1092056},"source":{"system":"sec-edgar","filing":"0000899243-23-012501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323012501/doc4.xml","form_type":"4"}},{"id":2040902,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":3,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":4,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":5,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":6,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":7,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":8,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":9,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2023-01-31T17:24:21.000Z","date":"2023-01-27","kind":"purchase","acquired":true,"shares":3133333,"price":1.5,"value":4699999.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures VII LP (\"ABV VII\"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any."}],"balance_after":8761891,"source":{"system":"sec-edgar","filing":"0000899243-23-003059","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323003059/doc4.xml","form_type":"4"}},{"id":2178790,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"exercise","acquired":false,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP."}],"balance_after":0,"derivative":{"exercise_price":11,"expiration_date":"2031-05-12","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178789,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":172,"price":21.0748,"value":3624.8656,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2960231,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178788,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":6472,"price":20.4201,"value":132158.8872,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2960403,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178787,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":3281,"price":19.8849,"value":65242.3569,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2966875,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178786,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"exercise","acquired":true,"shares":9925,"price":11,"value":109175.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2970156,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2312877,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-03-31T21:31:44.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":7720000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Soleno Therapeutics, Inc. (the \"Issuer\") are held by ABV VII. The Reporting Person holds the reported securities indirectly through ABV VII. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":7720000,"derivative":{"exercise_price":0.3,"exercise_date":"2022-03-29","expiration_date":"2027-03-29","underlying":"Common Stock","underlying_shares":7720000},"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2312876,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-31T21:31:44.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":31862,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests on the earlier of the twelve (12) month anniversary of June 1, 2021 or the day before the Issuer's next annual stockholder meeting, subject to Dr. Sinclair continuing to be a Service Provider through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":31862,"derivative":{"exercise_price":1.02,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":31862},"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2312875,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-31T21:31:44.000Z","date":"2021-01-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option fully vested on January 8, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":2.24,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2312874,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-31T21:31:44.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":9530,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option fully vested on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":9530,"derivative":{"exercise_price":3.41,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":9530},"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2312873,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-31T21:31:44.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option fully vested on May 17, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":13000,"derivative":{"exercise_price":2.5,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2312872,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-31T21:31:44.000Z","date":"2018-12-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in forty-eight (48) monthly installments commencing on December 21, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":20000,"derivative":{"exercise_price":1.57,"expiration_date":"2028-12-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2312871,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:31:44.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":7720000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Soleno Therapeutics, Inc. (the \"Issuer\") are held by ABV VII. The Reporting Person holds the reported securities indirectly through ABV VII. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":18022602,"source":{"system":"sec-edgar","filing":"0000905718-22-000523","document":"solenoth_fm4dec212018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571822000523/solenoth_fm4dec212018.xml","form_type":"4"}},{"id":2319886,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T21:30:38.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":78045,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option (the \"Option\") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The option (the \"Option\") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ABV VII may be deemed the indirect beneficial owner of the Option, and Mr. von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Mr. von Emster, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":78045,"derivative":{"exercise_price":3.54,"expiration_date":"2032-03-21","underlying":"Voting Common Stock","underlying_shares":78045},"source":{"system":"sec-edgar","filing":"0000905718-22-000484","document":"jasper_fm4mar212022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571822000484/jasper_fm4mar212022.xml","form_type":"4"}},{"id":2419086,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2022-02-01T17:00:39.000Z","date":"2022-01-28","kind":"other","acquired":false,"shares":287471,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":287471},"source":{"system":"sec-edgar","filing":"0000905718-22-000177","document":"sierraonco_fm4jan282022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000090571822000177/sierraonco_fm4jan282022.xml","form_type":"4"}},{"id":2419085,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2022-02-01T17:00:39.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":150000,"price":27,"value":4050000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1314127,"source":{"system":"sec-edgar","filing":"0000905718-22-000177","document":"sierraonco_fm4jan282022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000090571822000177/sierraonco_fm4jan282022.xml","form_type":"4"}},{"id":2419084,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2022-02-01T17:00:39.000Z","date":"2022-01-28","kind":"other","acquired":true,"shares":287471,"price":13.2,"value":3794617.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1164127,"source":{"system":"sec-edgar","filing":"0000905718-22-000177","document":"sierraonco_fm4jan282022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000090571822000177/sierraonco_fm4jan282022.xml","form_type":"4"}},{"id":2465429,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-17T21:30:28.000Z","date":"2021-10-06","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option (the \"Option\") was granted to Brian Gallagher (\"Gallagher\"), a director of the Issuer and a member of the investment committee of ABV VI (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Abingworth Bioventures VI GP LP (\"Abingworth GP\") serves as the general partner of Abingworth Bioventures VI, LP (\"ABV VI\"). Abingworth General Partner VI LLP serves as the general partner of Abingworth GP. ABV VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The option (the \"Option\") was granted to Brian Gallagher (\"Gallagher\"), a director of the Issuer and a member of the investment committee of ABV VI (the \"Investment Committee\") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and Gallagher may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. Each of ABV VI, Abingworth GP, Abingworth General Partner VI LLP, Gallagher, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":11.36,"expiration_date":"2031-10-05","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905718-21-001618","document":"effector_fm4oct62021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571821001618/effector_fm4oct62021.xml","form_type":"4"}},{"id":2707336,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T22:00:19.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options (the \"Options\") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster (\"Von Emster\"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The options (the \"Options\") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster (\"Von Emster\"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ABV 8 may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV 8. Abingworth LLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":9925,"derivative":{"exercise_price":11,"expiration_date":"2031-05-12","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0000905718-21-000712","document":"vera_fm4may132021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571821000712/vera_fm4may132021.xml","form_type":"4"}},{"id":2707335,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T22:00:19.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":772727,"price":11,"value":8499997.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures 8 LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2960231,"source":{"system":"sec-edgar","filing":"0000905718-21-000712","document":"vera_fm4may132021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571821000712/vera_fm4may132021.xml","form_type":"4"}},{"id":2707334,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T22:00:19.000Z","date":"2021-05-18","kind":"exercise","acquired":true,"shares":2187504,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures 8 LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2187504,"source":{"system":"sec-edgar","filing":"0000905718-21-000712","document":"vera_fm4may132021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571821000712/vera_fm4may132021.xml","form_type":"4"}},{"id":3001978,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-21T20:05:38.000Z","date":"2020-10-20","kind":"sale","acquired":false,"shares":130486,"price":27.66,"value":3609242.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3753340,"source":{"system":"sec-edgar","filing":"0000905718-20-001059","document":"personalis_fm4oct202020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001059/personalis_fm4oct202020.xml","form_type":"4"}},{"id":3002685,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-20T20:06:32.000Z","date":"2020-10-19","kind":"sale","acquired":false,"shares":196423,"price":27.86,"value":5472344.78,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $28.80 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3883826,"source":{"system":"sec-edgar","filing":"0000905718-20-001057","document":"personalis_fm4oct162020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001057/personalis_fm4oct162020.xml","form_type":"4"}},{"id":3002684,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-20T20:06:32.000Z","date":"2020-10-16","kind":"sale","acquired":false,"shares":94218,"price":26.68,"value":2513736.24,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $27.27 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4080249,"source":{"system":"sec-edgar","filing":"0000905718-20-001057","document":"personalis_fm4oct162020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001057/personalis_fm4oct162020.xml","form_type":"4"}},{"id":3004911,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-16T20:05:43.000Z","date":"2020-10-15","kind":"sale","acquired":false,"shares":3700,"price":26.32,"value":97384.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $26.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4174467,"source":{"system":"sec-edgar","filing":"0000905718-20-001051","document":"personalis_fm4oct142020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001051/personalis_fm4oct142020.xml","form_type":"4"}},{"id":3004910,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-16T20:05:43.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":81925,"price":27.08,"value":2218529.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4178167,"source":{"system":"sec-edgar","filing":"0000905718-20-001051","document":"personalis_fm4oct142020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001051/personalis_fm4oct142020.xml","form_type":"4"}},{"id":3006898,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-14T20:05:16.000Z","date":"2020-10-13","kind":"sale","acquired":false,"shares":86819,"price":28.43,"value":2468264.17,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.42 to $29.19 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\").  Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V.  ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4260092,"source":{"system":"sec-edgar","filing":"0000905718-20-001041","document":"personalis_fm4oct122020a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001041/personalis_fm4oct122020a.xml","form_type":"4"}},{"id":3006897,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-10-14T20:05:16.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":115541,"price":29.09,"value":3361087.69,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $30.72 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\").  Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V.  ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4346911,"source":{"system":"sec-edgar","filing":"0000905718-20-001041","document":"personalis_fm4oct122020a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820001041/personalis_fm4oct122020a.xml","form_type":"4"}},{"id":3050782,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2020-08-20T20:00:28.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":986842,"price":19,"value":18749998.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4462452,"source":{"system":"sec-edgar","filing":"0000905718-20-000875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571820000875/ownership.xml","form_type":"4"}},{"id":3088739,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-06T20:02:07.000Z","date":"2020-06-26","kind":"purchase","acquired":true,"shares":3333330,"price":1.65,"value":5499994.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on June 26, 2020. The shares are held by Abingworth Bioventures VII, LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10302602,"source":{"system":"sec-edgar","filing":"0000905718-20-000722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571820000722/ownership.xml","form_type":"4"}},{"id":3109011,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-16T22:26:05.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These options (the \"Option\") were granted to Kurt Von Emster (\"Von Emster\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These options (the \"Option\") were granted to Kurt Von Emster (\"Von Emster\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":16,"expiration_date":"2030-06-10","underlying":"Common Stock, $0.001 par value per share","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905718-20-000584","document":"vaxcyte_fm4ajun1520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000584/vaxcyte_fm4ajun1520.xml","form_type":"4/A","original_submission_date":"2020-06-15"}},{"id":3110570,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-15T20:41:13.000Z","date":"2020-06-11","kind":"grant","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These options (the \"Option\") were granted to Kurt Von Emster (\"Von Emster\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These options (the \"Option\") were granted to Kurt Von Emster (\"Von Emster\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":16,"expiration_date":"2030-06-10","underlying":"Common Stock, $0.001 par value per share","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905718-20-000582","document":"vaxcyte_fm4jun1120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000582/vaxcyte_fm4jun1120.xml","form_type":"4"}},{"id":3371073,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-11-14T21:12:58.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":126,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A convertible preferred stock (the \"Series A Stock\") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the \"Common Stock\"), at a price per share equal to $0.9949."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any \"group\" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures VI, LP (\"Abingworth\"). Abingworth Bioventures VI GP LP (\"Abingworth GP\") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2400,"derivative":{"exercise_price":0.9949,"exercise_date":"2017-06-22","underlying":"Common Stock, $0.001 par value","underlying_shares":126645},"source":{"system":"sec-edgar","filing":"0000905718-19-000932","document":"proteonther_fm4nov122019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000090571819000932/proteonther_fm4nov122019.xml","form_type":"4"}},{"id":3371072,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-14T21:12:58.000Z","date":"2019-11-12","kind":"exercise","acquired":true,"shares":126645,"price":0.9949,"value":125999.1105,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures VI, LP (\"Abingworth\"). Abingworth Bioventures VI GP LP (\"Abingworth GP\") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2144517,"source":{"system":"sec-edgar","filing":"0000905718-19-000932","document":"proteonther_fm4nov122019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000090571819000932/proteonther_fm4nov122019.xml","form_type":"4"}},{"id":3386259,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T20:01:08.000Z","date":"2019-10-25","kind":"purchase","acquired":true,"shares":2300000,"price":1.2,"value":2760000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures VII, LP (\"Abingworth VII\"). Abingworth Bioventures VII GP LP (\"Abingworth GP\") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6969272,"source":{"system":"sec-edgar","filing":"0000905718-19-000873","document":"soleno_fm4oct252019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484565/000090571819000873/soleno_fm4oct252019.xml","form_type":"4"}},{"id":3477871,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-06-26T10:53:39.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":878361,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock, $0.0001 par value per share","underlying_shares":878361},"source":{"system":"sec-edgar","filing":"0000905718-19-000553","document":"personalis_fm4jun242019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571819000553/personalis_fm4jun242019.xml","form_type":"4"}},{"id":3477870,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-06-26T10:53:39.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":2065217,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock, $0.0001 par value per share","underlying_shares":2065217},"source":{"system":"sec-edgar","filing":"0000905718-19-000553","document":"personalis_fm4jun242019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571819000553/personalis_fm4jun242019.xml","form_type":"4"}},{"id":3477869,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-06-26T10:53:39.000Z","date":"2019-06-24","kind":"exercise","acquired":false,"shares":2317073,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share (\"Common Stock\") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock, $0.0001 par value per share","underlying_shares":2317073},"source":{"system":"sec-edgar","filing":"0000905718-19-000553","document":"personalis_fm4jun242019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571819000553/personalis_fm4jun242019.xml","form_type":"4"}},{"id":3477868,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2019-06-26T10:53:39.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":878361,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":5449294,"source":{"system":"sec-edgar","filing":"0000905718-19-000553","document":"personalis_fm4jun242019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571819000553/personalis_fm4jun242019.xml","form_type":"4"}},{"id":3477867,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2019-06-26T10:53:39.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":2065217,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4570933,"source":{"system":"sec-edgar","filing":"0000905718-19-000553","document":"personalis_fm4jun242019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571819000553/personalis_fm4jun242019.xml","form_type":"4"}},{"id":3477866,"issuer":{"id":4572,"kind":"organization","name":"Personalis, Inc.","symbol":"PSNL"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2019-06-26T10:53:39.000Z","date":"2019-06-24","kind":"exercise","acquired":true,"shares":2317073,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Abingworth Bioventures V LP (\"Abingworth V\"). Abingworth Bioventures V GP LP (\"Abingworth GP\") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP (\"ALLP\"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2505716,"source":{"system":"sec-edgar","filing":"0000905718-19-000553","document":"personalis_fm4jun242019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571819000553/personalis_fm4jun242019.xml","form_type":"4"}},{"id":3898055,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-11T20:30:29.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":12700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By affiliate"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These options (the \"Options\") were granted to Tim Haines (\"Haines\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Haines and ALLP, Haines is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VI, and must exercise the Options solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Options, and Haines may be deemed the indirect beneficial owner of the Options through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Options except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Haines or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These options (the \"Options\") were granted to Tim Haines (\"Haines\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Haines and ALLP, Haines is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VI, and must exercise the Options solely upon the direction of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Options, and Haines may be deemed the indirect beneficial owner of the Options through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Options except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Haines or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12700,"derivative":{"exercise_price":2.5,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":12700},"source":{"system":"sec-edgar","filing":"0001171843-18-004576","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184318004576/formfour.xml","form_type":"4"}},{"id":3940581,"issuer":{"id":108294,"kind":"organization","name":"Sientra, Inc.","symbol":"SIEN"},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}}],"security":"Common Stock","published_at":"2018-05-09T21:10:33.000Z","date":"2018-05-07","kind":"purchase","acquired":true,"shares":281482,"price":13.5,"value":3800007.0,"ownership":{"direct":false,"nature":"See Notes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of (i) 1,240,247 shares held of record by Abingworth Bioventures V LP (\"ABV V\"), and (ii) 1,240,247 shares held of record by Abingworth Bioventures V Co-Invest Growth Equity Fund LP (\"AGE\"). ABV V and AGE are collectively referred to as the \"Abingworth Funds.\" The investment manager of the Abingworth Funds is Abingworth LLP (\"Abingworth\"). Abingworth Bioventures V GP LP (\"Abingworth GP\"), a Scottish limited partnership, serves as the general partner of each of the Abingworth Funds. Abingworth General Partner V LLP, a Scottish limited liability partnership, serves as the general partner of Abingworth GP. Abingworth GP (acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth all investment and dispositive power over the shares held by the Abingworth Funds. The reporting person holds the reported securities indirectly through the Abingworth Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, the Abingworth Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2480494,"source":{"system":"sec-edgar","filing":"0000905718-18-000472","document":"sientra_fm4may72018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397144/000090571818000472/sientra_fm4may72018.xml","form_type":"4"}},{"id":4272433,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2017-06-26T20:26:41.000Z","date":"2017-06-22","kind":"purchase","acquired":true,"shares":2526,"price":1000,"value":2526000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A convertible preferred stock (the \"Series A Stock\") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the \"Common Stock\"), at a price per share equal to $0.9949."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any \"group\" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by Abingworth Bioventures VI, LP (\"Abingworth\"). Abingworth Bioventures VI GP LP (\"Abingworth GP\") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2526,"derivative":{"exercise_price":0.9949,"exercise_date":"2017-06-22","underlying":"Common Stock, $0.001 par value","underlying_shares":2538949},"source":{"system":"sec-edgar","filing":"0000905718-17-000622","document":"abingworth_fm4jun222017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000090571817000622/abingworth_fm4jun222017.xml","form_type":"4"}},{"id":4275137,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":94434,"kind":"organization","name":"Abingworth LLP","position":1,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-21T20:15:49.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By affiliate"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on June 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) June 20, 2018 and (ii) the Issuer's next annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These options (the \"Options\") were granted to Tim Haines (\"Haines\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Haines and ALLP, Haines is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VI, and must exercise the Options solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Options, and Haines may be deemed the indirect beneficial owner of the Options through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Options except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Haines or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These options (the \"Options\") were granted to Tim Haines (\"Haines\"), a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between Haines and ALLP, Haines is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VI, and must exercise the Options solely upon the direction of ALLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Options, and Haines may be deemed the indirect beneficial owner of the Options through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Options except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Haines or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6666,"derivative":{"exercise_price":1.3,"expiration_date":"2027-06-19","underlying":"Common Stock, $0.001 par value","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001171843-17-003741","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184317003741/formfour.xml","form_type":"4"}}]}